A case report on the long-term survival of a patient with HER2-positive metastatic gastric adenocarcinoma and a short review of the current literature

被引：0
作者：
Hannah Christina Puhr
Aysegül Ilhan-Mutlu
机构：
[1] Medical University of Vienna,Department of Medicine I, Division of Oncology
[2] Medical University of Vienna,Comprehensive Cancer Centre Vienna, Upper Gastrointestinal Tumors Unit
来源：
memo - Magazine of European Medical Oncology | 2020年 / 13卷
关键词：
Gastric cancer; Upper GI cancer; HER2; Trastuzumab; Ramucirumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The prognosis of patients with metastatic gastroesophageal cancer remains poor despite numerous promising clinical trials, and the clinical benefit of systemic therapies is under critical review. This case report of a patient with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma is an impulse for the importance of individual decision making and molecular guided treatment options.
引用
收藏
页码：453 / 458
页数：5
相关论文
共 166 条
[1]  
Al-Batran S-E(2019)Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Lancet 393 1948-1957
[2]  
Homann N(2020)Trastuzumab with FLOT regimen for the perioperative treatment of resectable HER2 + advanced gastric cancer: a retrospective study Cancer Manag Res 12 2481-2489
[3]  
Pauligk C(2017)Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: petrarca—A phase II trial of the German AIO J Clin Oncol 35 TPS4133-1737
[4]  
Goetze TO(2010)Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis JAMA 303 1729-697
[5]  
Meiler J(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-1384
[6]  
Kasper S(2016)Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial BMC Cancer 16 68-451
[7]  
Tong G(2018)Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study Lancet Oncol 19 1372-6100
[8]  
Li S(2016)Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A randomized phase III trial J Clin Oncol 34 443-174
[9]  
Lin L(2018)Maintenance therapy with trastuzumab +/− fluoropyrimidine in non-progressive HER-2 positive advanced gastroesophageal cancer patients after first-line chemotherapy J Clin Oncol 11 6091-391
[10]  
He L(2018)Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer OTT 19 169-492
12345678910